New insights into the pathogenesis of Parkinson's disease (PD), the availability of a wider array of anti-parkinsonian therapies, the evolution of better tools for evaluating and monitoring disease progression have combined to change the current management of PD and the future landscape of PDrelated therapeutic clinical trials. This proposal outlines the key initial steps to develop the clinical trial methodology that allows for the longterm assessment of quality of life and economic outcomes in chronic neurological conditions. This will be accomplished by extending the duration of large multicenter clinical trial of pramipexole versus levodopa in early PD and augmenting the data collection effort to include clinical, quality of life, economic, and functional imaging outcomes. This will address questions for patients and providers on the best approach to treating early PD, as well as to provide a multidisciplinary research platform (clinical trials, quality of life assessment, and economic evaluation) to train a growing number of physician faculty and fellows at the University of Rochester in the theoretical, methodological, and practical knowledge and skills for a productive career in patient-oriented research. Dr. Holloway's position within the Departments of Neurology and Community and Preventive Medicine, and the Rochester Clinical Research Curriculum will ensure the recruitment of highly qualified trainees.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24NS042098-04
Application #
6793997
Study Section
NST-2 Subcommittee (NST)
Program Officer
Oliver, Eugene J
Project Start
2001-09-28
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
4
Fiscal Year
2004
Total Cost
$112,082
Indirect Cost
Name
University of Rochester
Department
Neurology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Young, Kate C; Holloway, Robert G; Burgin, W Scott et al. (2010) A cost-effectiveness analysis of carotid artery stenting compared with endarterectomy. J Stroke Cerebrovasc Dis 19:404-9
Dorsey, E Ray; Thompson, Joel P; Frasier, Mark et al. (2009) Funding of Parkinson research from industry and US federal and foundation sources. Mov Disord 24:731-7
O'Connor, Alec B; Noyes, Katia; Holloway, Robert G (2008) A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 26:1045-64
Frank, Samuel A; Wilson, Renee; Holloway, Robert G et al. (2008) Ethics of sham surgery: perspective of patients. Mov Disord 23:63-8
O'Connor, Alec B; Noyes, Katia; Holloway, Robert G (2007) A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 55:1176-84
Noyes, Katia; Dick, Andrew W; Holloway, Robert G (2007) The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 27:327-34
Dorsey, E R; Thompson, J P; Noyes, K et al. (2007) Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 68:1524-8
Noyes, Katia; Liu, Hangsheng; Holloway, Robert et al. (2007) Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov Disord 22:509-14
Noyes, Katia; Dick, Andrew W; Holloway, Robert G et al. (2006) Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 9:28-38
Noyes, Katia; Liu, Hangsheng; Holloway, Robert G (2006) What is the risk of developing parkinsonism following neuroleptic use? Neurology 66:941-3

Showing the most recent 10 out of 15 publications